1 Title Page

2	"Public attitudes to sharing government data with private industry: a systematic scoping
3	review."
4	Author(s):
5	Jackie Street ¹ , Stacy Carter ¹ , Belinda Fabrianesi ¹ , Rebecca Bosward ¹ , Lucy Carolan ^{1*} , Annette
6	Braunack-Mayer ¹
7	¹ University of Wollongong
8	*Corresponding author <u>lengland@uow.edu.au</u>
9	
10	Contribution(s):
11	JS conceptualised the study, contributed to data collection, analysis and interpretation, drafted and
12	approved the final manuscript.
13 14	SC contributed to the study concept and design, data analysis and interpretation, drafting the manuscript and approved the final manuscript
15	BF contributed to the study concept and design, data collection, data analysis and interpretation,
16	drafting the manuscript and approved the final manuscript
17	RB contributed to data collection, data analysis and interpretation, drafting the manuscript and
18	approved the final manuscript
19	LC contributed to the study concept and design, data analysis and interpretation, drafting the
20	manuscript and approved the final manuscript

ABM conceptualised the study, contributed to data analysis and interpretation, drafting the manuscript
and approved the final manuscript. ABM is responsible for obtaining the funding for the project and
is the corresponding author.

24

25 Abstract

26 Background: Linking and analysing large volumes of health data in electronic records, datasets, 27 registries and biobanks can provide detailed insights into the health profiles of individuals, 28 communities, regions and national populations. Good governance for data sharing can be challenging, 29 particularly when private sector organisations are the recipients of public sector data. Many 30 jurisdictions have responded by instituting new regulations and laws related to data protection, 31 responding to calls to promote data sharing and manage associated risks. This review integrates and 32 interprets five years of research on public and patient perspectives on sharing publicly-held health 33 data with private industry for research and development. Our review question was: what are 34 community attitudes towards the use of government administrative health data by private industry 35 organisations for therapeutic development?

Methods: We developed two logic grids: first, used terms describing citizens or patients, big data,
private health sector and views or perspectives, second, used terms describing big data, social licence
and public interest. We conducted a systematic literature search using electronic databases; PubMed,
Scopus, CINAHL, Web of Science. Searches were conducted using Google Advanced and Google
Scholar to identify grey literature

41 Results: A total of 6,788 articles were screened based on title and abstract. Full text screening was 42 conducted for 224 articles and a total of 33 publications were identified. Across all studies, support 43 for sharing administrative health data with private sector organisations was low. Background

knowledge and lack of trust that data use would lead to public benefit were the most importantreasons for low level of support.

46 Conclusion: Policymakers, data custodians and companies will need to establish robust safeguards 47 including secure storage, anonymisation, monitoring and independent oversight, and institute and 48 implement sanctions on misuse, if they are to secure legitimacy to share publicly-held health data with 49 private industry for research and development.

50 **Registration** *none available*.

51 Keywords: Big Data; Health Information Systems; Health Data; Private Sector; Data Linkage; Public

52 Opinion; Consent; Trust; Public Interest; Social License.

53

54 'Contributions to the literature'

- Research shows governance for data sharing is challenging, particularly when private sector
 organisations are the recipients of public sector data. Globally jurisdictions have responded by
 instituting new regulations and laws related to data protection, data sharing and the associated
 risks.
- Bringing together research on 'public attitudes towards the use of linked government
 administrative data by private sector organisations for therapeutic development', this
 systematic review found that public support for sharing was low.
- These findings highlight key areas for policymakers, data custodians and companies to
 address before they can legitimately share publicly-held health data with private industry for
 research and development.

65

66 "Public attitudes to sharing government data with private industry: a

67 systematic scoping review."

68 Introduction

Data are increasingly central to contemporary life and work, including in the health sector. Linking and analysing the very large volumes of health data in electronic health records, research datasets, registries and biobanks can provide detailed insights into the health profiles of individuals, communities, regions and national populations.

73 It is widely acknowledged that governance for data sharing is important. It is also challenging, 74 particularly when private sector organisations are the recipients of public sector data. (1-3) Concerns 75 about private sector use of public data can, in part, be traced to the profit-driven nature of private 76 sector companies. (4) Private companies are accountable to their shareholders and, at least in 77 countries such as Australia, are required to serve the interests of shareholders (5), potentially 78 conflicting with legislative requirements and public expectations that public sector administrative data 79 are used in the public interest. (6)

80 Many jurisdictions have responded to these challenges by instituting new regulations and laws related 81 to data protection, responding both to calls to promote data sharing (7-14) and to manage the risks 82 associated with sharing data. (1, 2) For example, the European Commission, in 2018, adopted the 83 General Data Protection Regulation (GDPR) giving individuals control over their personal data and 84 instituting large fines for privacy breaches. Other countries, including the US, (13) Canada (8) and 85 Australia, (9) are adopting legislative changes which will allow greater data sharing with the private 86 sector under supervision, (7-15) acknowledging both the important contribution that the private sector 87 makes to research and development of new pharmaceuticals and medical devices, and also noting the 88 challenge that sharing data with the private sector poses for public trust in government.

89 In light of such proposed changes, it is surprising that so little attention has been paid to public views90 about sharing administrative health data sets with the private sector. The evidence that is available is

91	scattered across papers that focus primarily on data sharing with other government agencies, with
92	researchers or with non-government organisations, rather than specifically with the private sector. (1)
93	Therefore, this paper brings together, for the first time, qualitative and quantitative research published
94	in the peer reviewed and grey literature on public attitudes towards the use of linked government
95	administrative data by private sector organisations for therapeutic development. Our review question
96	was:

What are community attitudes towards the use of government administrative health data by privateindustry organisations for therapeutic development?

99 Please refer to Additional file 1 for the PRISMA 2020 checklist/ reporting guidelines

- 100
- 101 Methods
- 102 Search strategy

103 In designing and conducting the scoping review, we drew on the work of Arksey and O'Malley (16) 104 and Peters et al. (17) Since we were primarily concerned with the breadth of existing literature in the 105 area, we did not exclude papers based on quality but used a Mixed Methods Appraisal Tool (18) to 106 note study limitations.

107 We developed two logic grids (population, concept, context, outcomes) for the study. The first search 108 used terms describing citizens or patients, big data, the private health sector and views or 109 perspectives, with these terms and relevant synonyms included in the searches. The second search 110 used terms describing Big Data, social licence and the public interest, with these terms and relevant 111 synonyms included in the Boolean searches. (For full details see Additional file 2, Supplementary 112 Tables S1 and S2). Depending on the database, documents were sourced within the time period "last 113 five years" or January 1st 2014 to April 1st 2019. We excluded papers published prior to 2014 114 because literature on sharing public health data with the private sector was limited prior to 2014. (1) 115 Earlier studies would not necessarily reflect current community views and judgements about the

public interest. Studies published within the time period, but which reported data prior to 2014, wereincluded.

118 We conducted a systematic literature search using four electronic databases PubMed, Scopus, 119 CINAHL, and Web of Science. In addition, searches were conducted using Google Advanced and 120 Google Scholar, in particular to identify relevant grey literature. These databases were selected for 121 their coverage of research with respect to the use of data analytics in health and, in particular, research 122 on community attitudes to data sharing in health. In Google Advanced and Google Scholar, searches 123 were restricted to the first 1000 hits. Additional 'pearled' relevant articles were extracted from the 124 reference lists of included papers. Peer-reviewed and unpublished articles, reports, books and book 125 chapters describing empirical research were included. Editorials or opinion pieces were excluded. 126 There were no limitations on geographical location but only English language articles were included.

For the database searches, we iteratively developed a search strategy based on the logic grid. Our final
search strategy is shown in Supplementary Tables S1 and S2. (Additional file 2, Supplementary
Tables S1-S4).

130

131 Inclusion/exclusion criteria

We screened title and abstract and, in the case of reports, the contents page using the criteria described in Table1. Articles were screened based on title and abstract (by authors JS, BF & RB). Full text screening was conducted by two authors (JS & BF). Where there was disagreement between the reviewers, the final decision for inclusion was made through discussion in the research team. Reference lists of included papers were reviewed and further articles identified.

137 ***TO BE INSERTED HERE**

- 138 (Additional file 3; **Table 1**: Inclusion and exclusion criteria for selection of articles)
- 139 Data extraction and analysis

140 A template for data extraction was used to provide a consistent approach to extraction and reporting 141 of the findings. Two reviewers (BF & JS) extracted: title, author name, year of publication, 142 location(s), aim(s), focus, public engaged, specific patient group, sample size, health technology, 143 methodology, models (consent, data linkage, public interest), case studies, overarching results -144 access of private companies to public data, under what circumstances can public data be shared with 145 private companies, consent, storage, definition of social /social contract, definition of public 146 interest/public benefits, and bias/limitations which related to the research questions. One reviewer, JS, 147 inductively coded, without a priori codes, the included articles using N-Vivo to extract descriptive 148 themes and develop analytical themes. A second reviewer, BF, coded two papers and used the 149 extracted data and the research question to cross-check the coding and extracted themes. Differences 150 were discussed and resolved.

151 <u>Table 2: Extracted Terms</u>

Ext	racted		
1	title	13	models:
2	author name		- consent
3	year of publication		- data linkage
4	location(s)		- public interest
5	aim(s)	14	overarching results:
6	focus		- access of private companies to public data
7	public engaged		- under what circumstances can public data be shared
8	specific patient group		- storage
9	sample size		- definition of social /social contract
10	health technology		

11	methodology	- definition of public interest/public benefits
12	case studies	- bias/limitations which related to the research questions.

153 Quality assessment

154 Study quality was assessed using the Mixed Methods Appraisal Tool (MMAT). This tool permits 155 appraisal of the studies in mixed methods systematic and scoping reviews. It is designed to appraise 156 the quality of the underpinning rationale and methodology. All studies meeting the inclusion criteria 157 were assessed using seven criteria. The first two criteria established the existence of a clear research 158 question while the second assessed the ability of the data collected to answer the question. The 159 remaining five criteria were related to the study type e.g. qualitative/quantitative. Studies were given a 160 score out of seven depending on how many of the criteria were met (18). Limitations of the studies are 161 discussed.

162

152

163 **Results**

A systematic literature search of the four electronic databases, Google Scholar and Google Advanced
generated the following number of articles: PubMed (797), Scopus (1,768), CINAHL (389), and Web
of Science (1,844), Google Scholar (1,990) and Google Advanced (293).

167 A total of 6,788 articles were screened based on title and abstract. Full text screening was conducted 168 by two authors (JS & BF) for 224 articles (which included an additional seven pearled articles) and a 169 total of 35 publications were identified. The flow chart in Figure 1 (see Additional file 4; Figure 1 170 PRISMA Flowchart) summarises the review selection process. Six papers scored below 5 on the 171 MMAT assessment tool with only one scoring less than 3.

172 Of the 35 publications included in the review, 22 were peer-reviewed papers, 10 reports, two

173 conference proceedings and one conference paper. Most papers reported on research conducted in the

United Kingdom (n=17) and United States (n=6), with smaller numbers in New Zealand (n=3),8

175 Canada (n=2), international (n=3), Europe (n=2), South Korea (n=1) and Thailand (n=1). There were 176 no studies identified from Australia, South America, Central America, Africa, Middle East, Russia or 177 for much of Europe or Asia. Data collection within the included studies occurred during the period 178 2007-2018. A small number of studies did not report their data collection period. Participants 179 included the broader public, affected patient groups, clinical stakeholders and private sector agencies. 180 In this paper, we only report the views of patients, consumers and broader publics.

Fourteen of the studies were qualitative or deliberative, using focus groups, citizen juries, workshops, social assembly and interviews. Sixteen of the studies were quantitative using online and in person surveys, and there were three mixed method studies. Two research studies were reported in duplicate reports, the Data Futures study in New Zealand (19, 20) and the Life and Times Survey in Northern Ireland (21, 22). All but one of the studies (23) scored more than 3 in the MMAT quality assessment tool. Scores are shown in Table 3.

187 ***TO BE INSERTED HERE**

- 188 (Additional file 5; **Table 3**: A summary of the publications included)
- 189

190 <u>Public support for sharing administrative health data</u>

191 In general, across all studies, support for sharing administrative health data with private sector 192 organisations was low. Eight quantitative studies specifically asked about sharing health data with 193 private sector organisations (Table 4). Most asked participants to rate how willing they were to share 194 information with a range of individuals and groups; participants were generally less willing to share 195 their non-identified data with private companies than with any other groups. (Table 4) The level of 196 support varied widely, with lower levels of support for sharing identifiable data (15%) (52) and higher 197 levels for a scenario involving the use of deidentified data to develop a cure for Alzheimer's Disease 198 (75%). (21) Similarly, in relevant qualitative studies, participants expressed less support for sharing 199 personal health data with for-profit private sector organisations when compared with other groups

200 involved in health research such as health care professionals, university researchers and non-profit

201 organisations. (20, 25, 26, 33, 35, 42, 43)

202 There were two underlying reasons for a low level of support for data sharing with the private sector: 203 background knowledge, and lack of trust that data use would lead to public benefit. With respect to 204 background knowledge, participants were reportedly often surprised about the extent of data use and 205 the possibility that their data might be shared with private companies. Because participants were not 206 able to draw on existing understandings about drug and device development, and data use and sharing, 207 the studies reported here either assumed familiarity with these issues or needed to include 208 explanations of them (e.g. private and public health sectors, big data, data collection, ownership and 209 sharing, health research governance and data safeguards). (4, 24, 27, 37, 38, 41-43, 47) Studies often 210 reported comments such as:

- Is this actually happening today, where they're collecting a lot of data? General Public,
 Focus Group 2, Toronto 2017 (43, p.E43)
- 213 *Private companies have no need to have my medical information.* General Public, Glasgow.
 214 2016 (4 p.36)
- *It says so they can predict what will make you ill or better. How? Are they god? How can they work all that out?* General public, Glasgow, 2016 (4, p.34)

In general, those studies that provided participants with opportunities to learn about data uses and safeguards reported that participants' willingness to share with private companies increased when their knowledge increased. (4, 26, 42, 49) For example, in deliberative workshops in Scotland, although participants were wary of private industry involvement, they acknowledged their involvement as "a necessary evil". (26, p.5)

222 The second background reason that participants rejected data sharing was a lack of trust that data use

would lead to public benefit. (20, 24, 26) Some participants suggested data use can be "a blunt

- instrument" which may do more harm than good. (20, p.12) Distrust extended to government and
- 225 universities but was highest for private industry. (20, 21, 24, 26, 42, 43, 47, 51) This lack of trust was 10

- 226 not a simple relationship but rather was based on a complex web of experiences, beliefs and
- knowledge described in more detail below.

228 ***TO BE INSERTED HERE**

- 229 (Additional file 6; **Table 4**: Proportion of participants willing to share administrative health data with
- 230 specific groups all quantitative studies asking this question).
- 231

232 <u>Concerns about sharing data with private industry</u>

The participants in the included studies were generally concerned about sharing their government health data. Some concerns were extensions of fears they had about sharing their health data with anyone, although their disquiet was intensified if the data sharing involved private industry. There were three main groups of concerns: about privacy, risk of harms, and use of public and personal data for private profits and interests. We discuss each of these in turn; more detail and sample quotes are presented in Supplementary Table S3. (Additional file 4, **Supplementary** Tables S1-S4)

239 Privacy and confidentiality

240 Many participants were concerned about loss of privacy and breaches of confidentiality. (4, 20, 24, 241 27, 33, 35-38, 42, 43, 48) In some studies, the terms 'privacy' and 'confidentiality' were used 242 interchangeably when describing participants' views about these matters (1, 38, 48), whilst in other 243 studies only 'privacy' or 'confidentiality' was used. (27, 33, 36, 43) One paper specifically noted that 244 study participants used the terms interchangeably, although the authors chose to use the term 245 confidentiality because it was the issue they were evaluating in their study (33). This paper 246 suggested that participants viewed maintaining confidentiality as an expression of respect "between 247 two parties exchanging information" and as a form of control, "a way of limiting how data about 248 oneself may be used by others", (33, p.965) with the former reflecting the duty of confidentiality and 249 the latter the maintenance of privacy.

Across studies, loss of privacy and breaches in confidentiality were often related back to inadequatedata security. Numerous studies reported concerns about data security, including the potential for

252 leaks and hacking, particularly when sharing data with private industry. (21, 23, 36, 37, 41-43, 47-49, 253 52) Concerns were in some cases related to the security of electronically stored data generally (4, 254 20, 42), but also to the belief that both public and private systems were leaky or unstable. (33, 36, 48) 255 This was based on knowledge of media reports of data breaches, (48) prior personal experience of 256 such breaches, perceptions that hospital record keeping was disorganised, (42) and concerns about the 257 stability of private companies. (36) There were also concerns about potential confidentiality breaches 258 and loss of privacy through on-selling data to other companies, particularly for marketing purposes. 259 (4, 24, 36, 41, 43, 49). The Wellcome Trust report on public attitudes to commercial access indicated 260 that, in their study, participants believed "that no amount of security could ever totally remove the 261 risks involved in sharing data". (4, p.11)

262 <u>Risk of Harm</u>

263 Concerns about data security were closely related to concerns about data misuse, expressed both in 264 terms of general uneasiness about the use of participants' data for purposes of which they were 265 unaware and might oppose (48) and, more particularly, the considerable potential for harms to 266 individuals through the use of identifiable health data. The latter included the use of their own data to 267 disadvantage them in employment, insurance cover, and financial and health care services. (4, 20, 27, 268 33-36, 38, 41-43, 47) Participants were also concerned that even aggregate data might be used to 269 stigmatise individuals based on their ethnicity or to segment, exploit or disadvantage vulnerable 270 groups. (4, 27) Some participants saw sharing data as one more sign that "we are heading for a 271 dystopian, surveillance-based society". (4, p.60) In a study involving older Swiss adults, participants 272 expressed concern about the potential use of data in eugenics:

So, my only concern is, it has once been talked about, that it could be used to create the
perfect human... or... that everyone would have blue eyes or a standard type or for military
purposes. Of course, that is a big topic. I would be absolutely against that. Female, age 69,
Switzerland (35, p.8)

12

- 277 Participants in this study were also concerned about becoming a "transparent citizen" with personal
- 278 knowledge about them accessible and available to many and that thereby "people or institutions ...
- 279 might gain unpredictable powers by it". (35, p.7).
- 280 <u>Use of data for private profit and private interests</u>
- 281 Although many participants acknowledged that there could be a role for commercial organisations in
- therapeutic development, at the same time they were concerned about the interests held by private
- industries [23, 29, 38, 45, 55], their lack of accountability (20, 42) and their focus on profit-making.
- 284 (4, 20, 26, 38, 42, 48) Across studies, the use of publicly held health data for private profit was a
- 285 common concern for a range of reasons. Some participants simply disliked the idea that private
- companies were making profit from their data, particularly without some measure of reciprocity:
- Business involved changes things a lot for me I'm unhappy with businesses getting personal
 data as they profit but don't have to give anything back. (20, p.13)
- Others believed that, unlike government organisations, private industry put their own interests ahead
 of the public good: (20, 26, 35, 42, 52)
- Unfortunately, my belief is that when people start making a profit out of it that's when the
 ethics start getting a little bit less and a little bit less as the profit margin goes up the less
 ethical you are the more money you earn. Participant 1, person with diabetes, London,
 UK:2016 (52, p.85)
- 295 They were concerned that the private sector had less oversight and were less accountable to the 296 public:
- *I'm fine with all of these organisations except businesses. Government usage is safer because there is responsible governance, but there is no corresponding obligation for private businesses who want to make a profit.* General public, New Zealand, including First Nations
 peoples, 2017 (20, p.13)

301 Some participants in Scottish deliberative workshops expressed a belief that private companies had
302 suppressed past 'cancer cures' and would suppress results in future research to increase their profits.
303 (26) In several UK studies participants expressed concern that pharmaceutical companies would
304 have access to publicly held health data to develop new drugs which they could then sell back to the
305 National Health Service (24, 41, 42) or on to others for profit. (4, 24, 38, 48, 49)

306 Participants in many studies differentiated between private companies using government health data

307 under regulated conditions for public benefit and unfettered access for generation of profit. (4, 21, 24-

308 27, 31, 35, 41-43) One parent of a child with a rare disease commented:

- 309Big pharma...Are they doing it with my consent, looking at a group to identify, make310progress, come up with treatments, understand conditions more I'd be comfortable with
- 311 that. Or are they just given free rein on my daughter's medical records so they can stabilize
- 312 *business, play entrepreneurs, gamble on it no that not OK.* Parent of patient, Sheffield, UK,
- **313** 2016 (4, p.57)

314 Finally, some participants saw the issue as ownership of the data and that industry use of government

data for private profit was an inappropriate use of their personal property (48)

316 Circumstances under which government health data may be shared

The concerns held by participants fed into their discussions about the conditions under which it would be acceptable for governments to share government-held administrative health data. Participants' concerns about the purpose for data sharing led to a requirement that research should produce public benefits; concerns about data security led to requirements for secure data storage and deidentification; and concerns about misuse led to requirements which would restrict access and protect the data.

- 323 There was substantial agreement across studies about the circumstances under which government324 health data could be shared. The primary requirements were that:
- the research should produce public benefits;
 - 14

326 the data should be secure as possible, particularly that it be de-identified and securely stored;

327

governance structures be in place to monitor and regulate access to data; and

328 that due reciprocity should be considered.

329 There were a range of views about whether informed consent for data use was necessary and the form

330 that consent should take. Here we discuss the principal conditions which participants believed were

331 necessary before data should be shared. A full list of can be found online in Supplementary Table S4.

332 (Additional file 4, Supplementary Tables S1-S4).

333 Public benefit

334 Although participants across studies considered it essential that the public should benefit from the 335 sharing of public administrative data with private industry, what constituted benefit varied widely. 336 (Table 5) In many studies (4, 20, 24-28, 31, 33, 41, 42, 51) public benefit was taken to mean 337 something "would (at least probably) ultimately lead to benefits for healthcare" (24, p.716) including 338 "finding cures for diseases and making new drugs available" (26, p.7) and monitoring the safety of 339 new health technologies. Cancer, dementia and mental health and research that improved health and 340 quality of life through preventive measures (see Table 5) were highlighted as important areas. Some 341 participants questioned the need for private industry to be involved: e.g. in a UK study using 342 deliberative workshops, participants valued monitoring for drug safety, but asked why the NHS could 343 not conduct this work itself. (4, p.51)

344 Participants with a history of personal or family illness were more likely to see data sharing, including 345 with private industry, as essential to support development of new treatments. (28, 33, 50)

346

Patients are key to advancing research by providing data to researchers —the more 347 information collected, the more it will promote advancement of research —in a rare disease 348 like this, maximum participation is required for effective research. Patients/relatives of 349 patients with leukodystrophies. (28, p.7)

15

350	But, even here, there were differences of opinion. Or	ne participant expressed strong opposition to					
351	sharing with private industry stating: "The Pharma indus	stry orients research in their own interests, not					
352	in the interests of patients." (28, p.340)						
353	Health benefit was also conceptualised as improving options for those with greatest need. For						
354	example, in deliberative workshops, Scottish participants acknowledged the merit in health research						
355	targeting "vulnerable groups who would potentially be	nefit the most" (26, p.7) and that benefits for					
356	small numbers of people could "lead to wider benefits for	pr society". (26, p.7)					
257							
307							
358							
359	Table 5: Conceptualisation of benefits through data link	tage and use					
	Concept	References					
	Disease diagnoses, treatments and cures (including	(4, 20, 21, 26, 28, 35, 37, 40-45, 47-53)					
	specifically cancer, dementia, mental health and rare						
	specifically cancer, dementia, mental health and rare diseases) to benefit both individuals and groups						
	specifically cancer, dementia, mental health and rare diseases) to benefit both individuals and groups Improved population health and wellbeing including	(26, 35, 38, 41, 42, 48, 49, 52)					
	specifically cancer, dementia, mental health and rarediseases) to benefit both individuals and groupsImproved population health and wellbeing includingthrough prevention	(26, 35, 38, 41, 42, 48, 49, 52)					
	specifically cancer, dementia, mental health and rarediseases) to benefit both individuals and groupsImproved population health and wellbeing includingthrough preventionMonitoring the long-term safety and efficacy of drugs	(26, 35, 38, 41, 42, 48, 49, 52) (4, 37, 40, 41, 43, 48, 49)					
	 specifically cancer, dementia, mental health and rare diseases) to benefit both individuals and groups Improved population health and wellbeing including through prevention Monitoring the long-term safety and efficacy of drugs and treatments 	(26, 35, 38, 41, 42, 48, 49, 52) (4, 37, 40, 41, 43, 48, 49)					
	 specifically cancer, dementia, mental health and rare diseases) to benefit both individuals and groups Improved population health and wellbeing including through prevention Monitoring the long-term safety and efficacy of drugs and treatments Improving health services and health outcomes for 	(26, 35, 38, 41, 42, 48, 49, 52) (4, 37, 40, 41, 43, 48, 49) (4, 20, 24, 26, 37, 38, 52)					
	specifically cancer, dementia, mental health and rare diseases) to benefit both individuals and groups Improved population health and wellbeing including through prevention Monitoring the long-term safety and efficacy of drugs and treatments Improving health services and health outcomes for vulnerable or disadvantaged populations	(26, 35, 38, 41, 42, 48, 49, 52) (4, 37, 40, 41, 43, 48, 49) (4, 20, 24, 26, 37, 38, 52)					
	specifically cancer, dementia, mental health and rare diseases) to benefit both individuals and groups Improved population health and wellbeing including through prevention Monitoring the long-term safety and efficacy of drugs and treatments Improving health services and health outcomes for vulnerable or disadvantaged populations Creation and dissemination of new knowledge	(26, 35, 38, 41, 42, 48, 49, 52) (4, 37, 40, 41, 43, 48, 49) (4, 20, 24, 26, 37, 38, 52) [29, 41, 51, 52]					
	specifically cancer, dementia, mental health and rare diseases) to benefit both individuals and groups Improved population health and wellbeing including through prevention Monitoring the long-term safety and efficacy of drugs and treatments Improving health services and health outcomes for vulnerable or disadvantaged populations Creation and dissemination of new knowledge Improved allocation of resources, cost-effective care	(26, 35, 38, 41, 42, 48, 49, 52) (4, 37, 40, 41, 43, 48, 49) (4, 20, 24, 26, 37, 38, 52) [29, 41, 51, 52] (26, 37, 41, 49)					

Improved health policy	(20, 37)
Giving "children the best start in life"	(4, 26, 35)
Improving the lives of older people	(26)
Improving the natural environment	(26)
Benefits for the environment	(26)
Access to a wider skill set if private industry is	(43)
involved	
Ability to detect rare health events	(37)

360

361

362 <u>Regulation and safeguards</u>

363 The participants in these studies wanted to see their data anonymised. Many studies did not discuss 364 the potential for reidentification and it may be that many participants were unaware that there was 365 potential for this to occur and, therefore, that they could never be completely anonymous. (20, 21, 23-366 25, 27, 30, 36, 37, 44, 47, 50, 52) From the participants' perspective, anonymisation of government 367 health data through removing personal information or aggregation was either a pre-requisite for 368 acceptance of data sharing (4, 25, 27, 33, 36, 44) or greatly increased willingness to share. (20, 24, 35, 369 37, 38, 41, 43, 47, 52) For example, in a large UK survey (n=2017) anonymity was seen as the second 370 most important condition for sharing health data with commercial organisations. (4) In a smaller 371 study, although just under half the participants (patients with diabetes n=404) indicated they would be 372 willing to share their government health data with pharmaceutical companies provided it was 373 anonymised, this fell to 15% if identifiers were retained. (52) In several UK studies, anonymisation 374 of data was seen as particularly important if data was to be shared with private companies: 375 participants were concerned that identifiable information could be misused and it may still be possible 376 to re-identify anonymised data. (4, 33, 48)

377 Most studies reported support for rigorous governance structures to monitor and regulate access to 378 government health data. In many studies participants wanted multiple safeguards to be instituted (4, 379 20, 24, 28, 36, 38) and some participants suggested that private entities might gain trust if they were 380 willing to "subject themselves to regulatory scrutiny". (4, p.56). In particular, participants called for 381 strict rules prohibiting passing data to third parties, anonymisation for data sharing, sanctions for 382 misuse of data, secure data storage and oversight by an ethics committee. (4) Monitoring of 383 individual access to the data by logging contact episodes was also suggested, the rationale being that 384 this would serve as a deterrent for malpractice.

- That would make me feel a bit more comfortable because they would know, if for any reason the system had been abused, not that it would be but they would know...There'll be a shortlist of people who have accessed, it would be a deterrent of abuse. General Public, Belfast, UK (4, p.63)
- Secure storage (4, 20, 21, 33, 36, 43, 48, 49, 52) and independent oversight. (4, 24, 25, 36-38, 43, 48,
 were widely recognised as essential conditions for data sharing. One participant in a European
 study likened the necessary controls to those found in the banking sector:
- *I'm just trying to say there is this framework, you know we say that there is a governance system in place which will protect the patient and we can look at them like we do the financial institutions and we're quite happy with how they exist, well they're quite well developed. There's a framework around this and we want some assurance.* Patients/parents of patients
 with a rare disease, Europe, (36, p.1,045)
- 397 One individual writing in response to attempts to share public administrative data sets in the UK said:
- I want the data to be supervised by an independent forum of individuals whose remit is to
 follow strict published ethical guidelines relating to sharing, selling and profit making by the
 use of my data. UK, Comment posted to website Care.data, 22.01.14 (48, p.184)
- 401 Scottish focus group participants suggested members of the public should have a role in an oversight
- 402 committee "ensuring accountability and protecting public interests". (24, p.720) Clear explanations18

403 about how data would be recorded, anonymised and stored was seen to be helpful in building support404 for data sharing:

405 He explained to me that basically there's only one location where there's a cross-reference
406 between the name of the participant and the identification process they're using on each
407 individual patient's, or study participant's, file. So I don't have any issues with that.

408 ClinSeq#120, NIH genomic research registry participant, USA (33, p.967)

- 409 Channelling information through trusted entities may increase public acceptance of data sharing but
- 410 some participants indicated that it could also erode trust in health care providers.
- 411 *I* do not trust the government with my data, and now I cannot trust my doctor o[r] the wider
- 412 *NHS*. Comment posted to Care.data website, 05.05.14, (48, p.183)

413 <u>Reciprocity</u>

414 Across studies, many participants called for a level of reciprocity from private companies receiving

415 administrative health data. This included that there be openness and transparency about how data were

416 stored, shared and used (4, 24, 27, 28, 33, 35, 38) as well as public release of the research findings. (4,

417 21, 24, 28, 30, 33, 38, 47) In addition, some participants called for access for research contributors to

418 their own data (28, 52) and for patient participants to any new technologies resulting from the

419 research. (41) Some believed that private industry should pay for data access or, where applicable,

420 deliver some of the ensuing profit back into the public system. (21, 22, 38, 41-43)

421 <u>Consent</u>

422 Consent was an important consideration in many studies but the need for and type of consent was 423 highly contentious. (4, 20, 27-29, 31, 33, 36) Some participants were comfortable with government 424 health data sharing with no consent - particularly where data were anonymised or aggregated and the 425 research of high public benefit - whereas others wanted explicit consent on every occasion. The 426 majority of participants in two deliberative studies that explicitly focused on sharing with private 427 industry started from a position of requiring informed consent but moved to no-consent required for 428 cases with high public benefit where consent was impossible or prohibitively expensive. (4, 49)

429	Participants in one of the studies called for better communication around data use without consent (4)
430	and some participants suggested that their ongoing reservations related to a lack of clarity about the
431	personal implications of sharing their data with private industry. (4, 33) Some members of the NICE
432	Citizens' Council became more concerned following deliberation. One participant reflecting this shift
433	said:

434 "I've completely changed my mind. When I first started [the meeting] I thought 'yeah', but
435 now all I can think of is cons." NICE Citizens Council (41, p.23)

436 **Discussion**

This scoping review integrates and interprets five years of research on public and patient perspectives on sharing publicly-held health data with private industry for research and development. Many studies noted that publics and patients have limited opportunities to understand the nature and extent of data use, sharing and protection; researchers consequently provided information to participants as part of the research process in a number of the included studies. Our findings are consistent with other systematic reviews of international perspectives on health data sharing. (1, 54, 55) Our first conclusion is:

444 1) People support sharing public sector health data for health research in general, but are less
445 willing to share with the private sector for research and development.

This conclusion is consistent with research on general public attitudes to sharing, and with research on public attitudes to: sharing genomic data (56)(56), secondary use of clinical trial or public health study data (57), and "broad consent" for data sharing. (2) We thus suggest this central finding is robust, at least within the UK and North American settings (where most research has been conducted). (1, 54, 55) Further research is necessary to understand generalisability to other contexts. Participants expressed concerns regarding perceived *vulnerabilities in data security*, potential for *misuse of data*, and potential for *discrimination* against, or *stigmatisation* of, individuals or groups.

453 Quantified measures of support for sharing health data with private actors ranged from 16% to 75%

- 454 (i.e. from on-balance rejection to on-balance acceptance). This leads to our second conclusion:
- 455 2) Public support for sharing public sector health data with the private sector is possible, but is
 456 more strongly conditional than support for sharing with public sector and non-profit actors.

457 Our review suggests that any government, agency or company considering public-private health data 458 sharing needs to develop a social licence, and that this will require providing, negotiating and assuring 459 granular commitments regarding what data are shared, why they are shared, how identification is 460 handled, and the governance and accountability mechanisms in place (Table 4). In particular, publics 461 expect that data sharing should produce *public benefit*, that safeguards including secure storage, 462 anonymisation, monitoring and independent oversight would be in place, and that sanctions would 463 follow misuse. While other reviews have reported similar expectations with respect to sharing in 464 general, (1, 54, 55) this review adds clear evidence that these expectations become far stronger when 465 data are shared with private industry. These higher expectations for public-private sharing were 466 informed by disquiet about using a public resource for private profit. A profit motive was seen to 467 exacerbate the risks that participants were concerned about: security, misuse, and potential for harm 468 (e.g. via stigmatisation or discrimination). (4, 49) For-profit use was also seen to undermine a non-469 negotiable and central condition for sharing: that data be used for public benefit or the public good 470 (which could include aggregative benefit to individuals).

471 Similar to other reviews (1, 54, 55), we found public benefit was also highly relevant to consent

- 472 requirements. This leads to our third conclusion:
- 473 3) Preferences regarding consent models reflect judgements regarding two underpinning
 474 considerations: whether the parties involved can be trusted, and the likely public benefit from
 475 sharing data.

476 Generally higher trust and/or higher public benefit allowed acceptance of consent models with lower
477 individual control. However, for some participants, if data sharing involved private industry, explicit
478 consent was essential even if public benefit was high. In systematic reviews of public attitudes 21

479 towards sharing of genomic data, and secondary use of research data, individual-level consent has 480 been seen as a way to address concerns (e.g., about security, misuse and harm) (56, 57). Note, 481 however, it is generally considered logistically infeasible to obtain individual consent for each act of 482 sharing administrative health data. Also, individual-level consent may make a dataset less 483 representative, or systematically biased, due to uneven non-participation, making findings 484 untrustworthy. If active consent is seen as the only way to secure socially acceptable sharing with 485 private industry, such sharing may be impossible. Further research is needed to explore alternative 486 ways to develop the social licence to share data with the private sector. For example, our own 487 research using deliberative methods suggests that informed citizens may be willing to accept sharing 488 their data, including with private industry, provided sharing is tightly regulated and in the public 489 interest (58).

490

491 **Study Limitations**

492 Six of the articles scored less than 5 using the MMAT tool and 3 had a score of less than 4. One 493 paper, reporting a single focus group, had a score of 1 and, although noted, was not included in the 494 findings of the review.

495 **Conclusion**

496 Overall, this review has indicated key areas for policymakers, data custodians and companies to 497 address if they are to secure legitimacy for the sharing of publicly-held health data with private 498 industry for research and development. Each program of data sharing would require carefully 499 negotiated commitments to establish safeguards including secure storage, anonymisation, monitoring 500 and independent oversight, and to institute and implement sanctions on misuse. Patients and publics 501 would require assurance that data use will lead to public benefit, and that all actors and systems 502 involved are trustworthy. These things may be achievable, but two problems currently appear 503 intractable. When data are shared for private profit, publics—quite reasonably—recognise a conflict

22

504	of interest and are thus less likely to trust safeguards or assurances. Without both trust and assurance
505	of public benefit, public-private data sharing is unlikely to be supported. In situations of lower trust
506	and/or lower public benefit, publics are more likely to expect that they will have an opportunity to
507	provide individual consent for instances of sharing, which is potentially fatal to the data sharing
508	enterprise. More research is required to determine how this conundrum can be addressed.
509	
510	Declarations
511	• Ethics approval and consent to participate
512	Not applicable
513	Consent for publication
514	Not applicable
515	Availability of data and materials
516	Data sharing is not applicable to this article as no datasets were generated or analysed during
517	the current study.
518	Competing interests
519	The authors declare that they have no competing interests
520	• Funding
521	Funded by the Population Health Research Network
522	Authors' contributions

- 523 JS conceptualised the study, contributed to data collection, analysis and interpretation, drafted
- 524 and approved the final manuscript.
- 525 SC contributed to the study concept and design, data analysis and interpretation, drafting the
- 526 manuscript and approved the final manuscript
- 527 BF contributed to the study concept and design, data collection, data analysis and 528 interpretation, drafting the manuscript and approved the final manuscript
- 529 RB contributed to data collection, data analysis and interpretation, drafting the manuscript 530 and approved the final manuscript
- 531 LC contributed to the study concept and design, data analysis and interpretation, drafting the 532 manuscript and approved the final manuscript
- 533 ABM conceptualised the study, contributed to data analysis and interpretation, drafting the 534 manuscript and approved the final manuscript. ABM is responsible for obtaining the funding
- 535 for the project and is the corresponding author.

536

537 Acknowledgements

538 The authors would like to thank the Population Health Research Network for funding the 539 project, The content is solely the responsibility of the authors and does not represent the 540 views of the Population Health Research Network.

- 541
 - **Authors additional information**
- 542 1. Dr Jackie Street, ACHEEV, School of Health and Society, Faculty of the Arts, Social 543 Sciences and Humanities, University of Wollongong NSW 2522 Australia
- 544 streetj@uow.edu.au
- 545 ORCID # 0000-0002-1033-4341
- 546 2. Prof Stacy Carter, ACHEEV, School of Health and Society, Faculty of the Arts, Social 547 Sciences and Humanities, University of Wollongong NSW 2522 Australia
- 548 stacyc@uow.edu.au
 - 24

549		ORCID # 0000-0003-2617-8694
550	3.	Belinda Fabrianesi, ACHEEV, School of Health and Society, Faculty of the Arts, Social
551		Sciences and Humanities, University of Wollongong NSW 2522 Australia
552		belindaf@uow.edu.au
553		ORCID # 0000-0001-8134-7900
554	4.	Rebecca Bosward
555		ACHEEV, School of Health and Society, Faculty of the Arts, Social Sciences and
556		Humanities, University of Wollongong NSW 2522 Australia
557		rbosward@uow.edu.au
558		ORCID # 0000-0002-3368-0781
559	5.	Lucy Carolan, ACHEEV, School of Health and Society, Faculty of the Arts, Social Sciences
560		and Humanities, University of Wollongong NSW 2522 Australia
561		lengland@uow.edu.au
562		ORCID # 0000-0002-8116-4036
563	6.	Prof Annette Braunack-Mayer, ACHEEV, Australian Centre for Health Engagement,
564		Evidence and Values, School of Health and Society, Faculty of the Arts, Social Sciences and
565		Humanities, University of Wollongong NSW 2522 Australia
566		abmayer@uow.edu.au, (corresponding author)
567		ORCID # 0000-0003-4427-0224
568		
569		

570 **References**

Aitken M, de St Jorre J, Pagliari C, Jepson R, Cunningham-Burley S. Public responses to the
 sharing and linkage of health data for research purposes: a systematic review and thematic synthesis

- 573 of qualitative studies. BMC Medical Ethics. 2016;17(1):73. https://doi.org/10.1186/s12910-016-0153-
- 574 x
- 575 2. Garrison NA, Sathe NA, Antommaria AH, Holm IA, Sanderson SC, Smith ME, et al. A
- 576 systematic literature review of individuals' perspectives on broad consent and data sharing in the
- 577 United States. Genetics in Medicine. 2016;18(7):663-71. https://doi.org/10.1038/gim.2015.138
- 578 3. Hill EM, Turner EL, Martin RM, Donovan JL. "Let's get the best quality research we can":
- 579 Public awareness and acceptance of consent to use existing data in health research: a systematic
- review and qualitative study. BMC medical research methodology. 2013;13:72.
- 581 https://doi.org/10.1186/1471-2288-13-72
- 582 4. Ipsos MORI For the Wellcome Trust. The One-Way Mirror: Public attitudes to commercial
- 583 access to health data. London, UK: Wellcome Trust; 2016. Retrieved from:
- 584 https://wellcome.figshare.com/articles/The_One_Way_Mirror_Public_attitudes_to_commercial_acces
- 585 s_to_health_data/5616448
- 586 5. Commonwealth of Australia, (2001) Corporations Act Retreived from:
- 587 https://www.legislation.gov.au/Details/C2019C00216
- 588 6. Laurie G, Stevens L. Developing a Public Interest Mandate for the Governance and Use of
- 589 Administrative Data in the United Kingdom. Journal of Law and Society. 2016;43(3):360-92.
- 590 https://doi.org/10.1111/j.1467-6478.2016.00759.x
- 591 7. Australian Government. 2016 National Research Infrastructure Roadmap. 2017. Retrieved
- from: https://www.dese.gov.au/national-research-infrastructure/resources/2016-national-research-
- 593 infrastructure-roadmap
- 594 8. Canadian Government. *Personal Information Protection and Electronic Documents Act*
- 595 (PIPEDA). 2015 (Amended). Retreived from: https://www.priv.gc.ca/en/privacy-topics/privacy-laws-
- 596 in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/

597	9.	Commonwealth of A	ustralia. Data	Availability and	Transparency	Bill 2020, F	Exposure Draft
~ ~ .	· · ·						

- 598 In: House of Representatives, editor. Canberra: Commonwealth of Australia; 2020. Retreived from:
- 599 https://www.aph.gov.au/Parliamentary_Business/Bills_Legislation/bd/bd2122a/22bd018
- 10. Davidson S, McLean C, Treanor S, Aitken M, Cunningham-Burley S, Laurie G, et al. Public
- 601 Acceptability of Data Sharing Between the Public, Private and Third Sectors for Research Purposes.
- 602 In: Scottish Government Retrieved from: http://www.scotland.gov.uk/resource/0043/00435458.pdf
- 603 11. European Commission. Public-Private Partnership (PPP) for Big Data. 13th October 2014.
- 604 Retrieved from: https://ec.europa.eu/commission/presscorner/detail/en/MEMO_14_583
- 605 12. Scottish Government. Joined up data for better decisions: A strategy for improving data
- access and analysis. In: Government S, editor. Edinburgh: Scottish Government; 8th November 2012.
- 607 Retreived from: https://www.gov.scot/publications/joined-up-data-better-decisions-strategy-
- 608 improving-data-access-analysis/
- 609 13. State of California. California Consumer Privacy Act of 2018 (CCPA) 2018. Retreived from
- 610 https://iapp.org/train/ccpa-ready/?gclid=CjwKCAjwjZmTBhB4EiwAynRmD4LKM-
- 611 E6tsyRmK0JZwIywvFyPRsLW20XNLLS5OV5ZPCTfOhS7UiYpRoCc9cQAvD_BwE
- 612 14. United Kingdom Government. Guidance, Joined up data in government: the future of data
- 613 linking methods. Office for National Statistics,; 2020. Retrieved from:
- 614 https://www.gov.uk/government/publications/joined-up-data-in-government-the-future-of-data-
- 615 linking-methods/joined-up-data-in-government-the-future-of-data-linkage-methods
- 616 15. European Commission. Regulation of the European Parliament and of the Council on
- 617 European Data Governance, Data Governance Act. In: Commission E, editor. Document
- 618 52020PC0767. Brussels: European Commission; 2020. Retrieved from: https://eur-
- 619 lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:52020PC0767

- 620 16. Arksey H, O'Malley L. Scoping studies: Towards a methodological framework. International
- 621 Journal Social Research Methodology. 2005;8(1):19-32.
- 622 https://doi.org/10.1080/1364557032000119616
- 623 17. Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Baldini C. Guidance for
- 624 conducting systematic scoping reviews. International Journal of Evidence-Based Healthcare.
- 625 2015;13:141-6. https://doi.org/10.1097/xeb.0000000000000000
- 626 18. Hong QN, Pluye P, Fabreugues S, Bartlett G, Boardman F, Cargo M, et al., inventorsMixed
- 627 methods appraisal tool (MMAT) Version 20182018. Retreived from: https://htai.org/wp-
- 628 content/uploads/2018/08/HTAi2018_VP26_ACriticalAppraisal.pdf
- 629 19. Brown A, Parkin T, Tobin A, Le Bas T. Our Data, Our Way: What New Zealand people
- 630 expect from guidelines for data use and sharing. Feb/ March 2017. Retreived from:
- 631 https://www.toiaria.org/our-projects/our-data-our-way/
- 632 20. Data Futures Partnership. A Path to Social Licence: Guidelines for Trusted Data Use. New
- 633 Zealand August 2017. Retrieved from: https://trusteddata.co.nz/wp-
- 634 content/uploads/2017/08/Summary-Guidelines.pdf
- 635 21. Robinson G, Dolk H. Public attitudes to data sharing in Northern Ireland. Ulster:
- 636 Administratrive Data Research Centre Northern Ireland (ARK); August 2015. Retreived from:
- 637 https://research.hscni.net/sites/default/files/0032-RESEARCH%20UPDATE%20108%20final.pdf
- 638 22. Robinson G, Dolk H, Dowds L, Given J, Kane F, Nelson E. Public attitudes to data sharing in
- 639 Northern Ireland: Findings from the 2015 Northern Ireland life and times survey. Ulster:
- 640 Administratrive Data Research Network; Public Health Agency; Ulster University; February 2018.
- 641 Retreived from: https://www.ark.ac.uk/pdfs/Researchreports/Data_Sharing_Report.pdf
- 642 23. Satinsky EN, Driessens C, Crepaz-Keay D, Kousoulis A. Mental health service users'
- 643 perceptions of data sharing and data protection: a qualitative report. Journal of Innovation in Health
- 644 Informatics. 2018;25(4):239-42. http://dx.doi.org/10.14236/jhi.v25i4.1033

- 645 24. Aitken M, Cunningham-Burley S, Pagliari C. Moving from trust to trustworthiness:
- 646 Experiences of public engagement in the Scottish Health Informatics Programme. Science and Public
- 647 Policy. 2016;43(5):713-23. https://doi.org/10.1093/scipol/scv075
- 648 25. Aitken M, McAteer G, Davidson S, Frostick C, Cunningham-Burley S. Public Preferences
- 649 regarding Data Linkage for Health Research: A Discrete Choice Experiment. International Journal of
- 650 Population Data Science. 2018;3(1). https://dx.doi.org/10.23889%2Fijpds.v3i1.429
- 651 26. Aitken M, Porteous C, Creamer E, Cunningham-Burley SJBD. Who benefits and how? Public
- expectations of public benefits from data-intensive health research. Big Data and Society.
- 653 2018;5(2):1-12. . https://doi.org/10.1177%2F2053951718816724
- 654 27. Cheah PY, Jatupornpimol N, Hanboonkunupakarn B, Khirikoekkong N, Jittamala P,
- 655 Pukrittayakamee S, et al. Challenges arising when seeking broad consent for health research data
- sharing: a qualitative study of perspectives in Thailand. BMC medical ethics. 2018;19(1):86.
- 657 https://doi.org/10.1186/s12910-018-0326-x
- 28. Darquy S, Moutel G, Lapointe A-S, D'audiffret D, Champagnat J, Guerroui S, et al.
- 659 Patient/family views on data sharing in rare diseases: study in the European LeukoTreat project.
- 660 European Journal of Human Genetics. 2016;24(3):338. https://dx.doi.org/10.1038%2Fejhg.2015.115
- 661 29. Davison A, Beetham J, Thomas J, Harding A, Ivory V, Bowie C. Public attitudes to data
- 662 integration. Lower Hutt, New Zealand: Report prepared by OPUS International Consultants for
- 663 Statistics New Zealand; 2015. https://www.stats.govt.nz/assets/Uploads/Retirement-of-archive-
- 664 website-project-files/Corporate/Public-attitudes-to-data-integration/public-attit-data-integr-2015.pdf
- 665 30. Goodman D, Johnson CO, Bowen D, Smith M, Wenzel L, Edwards K. De-identified genomic
- data sharing: the research participant perspective. Journal of community genetics. 2017;8(3):173-81.
- 667 https://doi.org/10.1007/s12687-017-0300-1

- 668 31. Grande D, Mitra N, Shah A, Wan F, Asch DA. The importance of purpose: Moving beyond
- 669 consent in the societal use of personal health information. Annals of Internal Medicine.
- 670 2014;161(12):855-62. https://doi.org/10.7326/M14-1118
- 671 32. Huskison T, Gilby N, Evans H, Stevens J, Tipping S, Ipsos MORI. Wellcome Trust Monitor
- Wave 3: Chapter 6. Participation in Medical Research. London UK: Wellcome Trust; 2016.
- 673 https://doi.org/10.7326/M14-1118
- 33. Jamal L, Sapp JC, Lewis K, Yanes T, Facio FM, Biesecker LG, et al. Research participants'
- attitudes towards the confidentiality of genomic sequence information. European Journal of Human
- 676 Genetics. 2014;22(8):964-8. . https://doi.org/10.1038/ejhg.2013.276
- 677 34. Kim TK, Choi M. Older adults' willingness to share their personal and health information
- 678 when adopting healthcare technology and services. International Journal of Medical Informatics.
- 679 2019;126:86-94. https://doi.org/10.1016/j.ijmedinf.2019.03.010
- 680 35. Mählmann L, Schee Gen Halfmann S, Von Wyl A, Brand A. Attitudes towards personal
- 681 genomics and sharing of genetic data among older swiss adults: A qualitative study. Public Health
- 682 Genomics. 2018;20(5):293-306. https://doi.org/10.1159/000486588
- 683 36. McCormack P, Kole A, Gainotti S, Mascalzoni D, Molster C, Lochmüller H, et al. 'You
- should at least ask'. The expectations, hopes and fears of rare disease patients on large-scale data and
- biomaterial sharing for genomics research. Eur J Hum Genet. 2016;24(10):1403-8.
- 686 https://doi.org/10.1038/ejhg.2016.30
- 687 37. McCormick N, Hamilton C, Koehn CL, English K, Stordy A, Li L. Canadians' Views about
- 688 Using Big Data in Health Research from a National Online Survey: A Partnership of Patient-
- 689 Consumers and Researchers. Arthritis & Rheumatology. 2018;70. Retreived from:
- 690 https://acrabstracts.org/abstract/canadians-views-about-using-big-data-in-health-research-from-a-
- 691 national-online-survey-a-partnership-of-patient-consumers-and-researchers/

- 692 38. Mazor KM, Richards A, Gallagher M, Arterburn DE, Raebel MA, Nowell WB, et al.
- 693 Stakeholders' views on data sharing in multicenter studies. Future Virology. 2017;12(9):537-47.
- 694 https://doi.org/10.2217/cer-2017-0009
- 695 39. Moss L, Shaw M, Piper I, Hawthorne C, Kinsella J. Sharing of big data in healthcare: Public
- opinion, trust and privacy considerations for health informatics researchers. 10th International
- 697 Conference in Health Informatics; Porto, Portugal2017. Retreived from:
- 698 http://eprints.gla.ac.uk/168346/
- 40. Mursaleen LR, Stamford JA, Jones DA, Windle R, Isaacs T. Attitudes Towards Data
- 700 Collection, Ownership and Sharing Among Patients with Parkinson's Disease. Journal of Parkinson's
- 701 disease. 2017;7(3):523-31. https://doi.org/10.3233/jpd-161045
- 41. Nice Citizens Council. NICE Citizens Council Reports. What Ethical and Practical Issues
- 703 Need to Be Considered in the Use of Anonymised Information Derived from Personal Care Records
- as Part of the Evaluation of Treatments and Delivery of Care? London: National Institute for Health
- and Care Excellence (NICE); 2015. Retreived from: https://pubmed.ncbi.nlm.nih.gov/28230945/

706

- 42. Papoutsi C, Reed JE, Marston C, Lewis R, Majeed A, Bell D, et al. Patient and public views
- about the security and privacy of Electronic Health Records (EHRs) in the UK: results from a mixed
- 709 methods study. BMC Medical Informatics. 2015;15(1):86. https://doi.org/10.1186/s12911-015-0202-2
- 710 43. Paprica PA, de Melo MN, Schull MJ. Social licence and the general public's attitudes toward
- research based on linked administrative health data: a qualitative study. CMAJ open. 2019;7(1):E40.
- 712 https://doi.org/10.9778/cmajo.20180099
- 713 44. Pickard KT, Swan M, editors. Big desire to share big health data: A shift in consumer
- attitudes toward personal health information. AAAI; 2014; Quebec City. Retreived from:
- 715 https://www.semanticscholar.org/paper/Big-Desire-to-Share-Big-Health-Data%3A-A-Shift-in-
- 716 Pickard-Swan/846c3316daa8af7964042bfd29759a8e5589b627

31

- 717 45. Platt J, Bollinger J, Dvoskin R, Kardia SL, Kaufman D. Public preferences regarding
- 718 informed consent models for participation in population-based genomic research. Genetics in
- 719 Medicine. 2014;16(1):11. https://dx.doi.org/10.1038%2Fgim.2013.59
- 46. Platt JE, Jacobson PD, Kardia SLR. Public Trust in Health Information Sharing: A Measure
- 721 of System Trust. Health Serv Res. 2018;53(2):824-45. https://doi.org/10.1111/1475-6773.12654
- 722 47. Spencer K, Sanders C, Whitley EA, Lund D, Kaye J, Dixon WG. Patient perspectives on
- sharing anonymized personal health data using a digital system for dynamic consent and research
- feedback: a qualitative study. Journal of Medical Internet Research. 2016;18(4):e66.
- 725 https://dx.doi.org/10.2196%2Fjmir.5011
- 48. Sterckx S, Rakic V, Cockbain J, Borry P. "You hoped we would sleep walk into accepting the
- 727 collection of our data": controversies surrounding the UK care. data scheme and their wider relevance
- for biomedical research. Medicine Health Care and Philosophy. 2016;19(2):177-90.
- 729 http://dx.doi.org/10.1007/s11019-015-9661-6
- 730 49. Tully MP, Bozentko K, Clement S, Hunn A, Hassan L, Norris R, et al. Investigating the
- 731 extent to which patients should control access to patient records for research: A deliberative process
- vising citizens' juries. Journal of Medical Internet Research. 2018;20(3).
- 733 https://doi.org/10.2196/jmir.7763
- 50. West B, Cumella A. Data sharing and technology: Exploring the attitudes of people with
- asthma. report London: Asthma UK; 2018. Retrieved from:
- 736 https://www.asthma.org.uk/8195030f/globalassets/get-involved/external-affairs-
- 737 campaigns/publications/data-report/data-sharing-and-technology---exploring-the-attitudes-of-people-
- 738 with-asthma.pdf
- 51. United Kingdom Government. Knowledge & Opinion [Internet]. (ODI) ODI, editor. UK
- 740 2018. Available from: <u>https://theodi.org/article/odi-survey-reveals-british-consumer-attitudes-to-</u>
- 741 sharing-personal-data/.
 - 32

- 742 52. Zalin A, Papoutsi C, Shotliff K, Majeed A, Marston C, Reed J. The use of information for
- 743 diabetes research and care: Patient views in West London. Practical Diabetes. 2016;33(3):81-6a.
- 744 https://doi.org/10.1002/pdi.2008
- 53. Data Futures Partnership. Data Futures Partnership: A Path to Social Licence: Guidelines for
- 746 Trusted Data Use. In. New Zealand 2017.
- 747 54. Kalkman S, Delden Jv, Banerjee A, Tyl B, Mostert M, Thiel Gv. Patients' and public views
- and attitudes towards the sharing of health data for research: a narrative review of the empirical
- evidence. Journal of Medical Ethics. 2019;Published Online First: 12 November 2019. doi:
- 750 10.1136/medethics-2019-105651.
- 55. Stockdale J, Cassell J, Ford E. "Giving something back": A systematic review and ethical
- r52 enquiry into public views on the use of patient data for research in the United Kingdom and the
- 753 Republic of Ireland. Wellcome open research. 2019;3:6.
- https://doi.org/10.12688/wellcomeopenres.13531.2
- 56. Shabani M, Bezuidenhout L, Borry P. Attitudes of research participants and the general
- 756 public towards genomic data sharing: a systematic literature review. Expert Review of Molecular
- 757 Diagnosis. 2014;14(8):1053-65. https://doi.org/10.1586/14737159.2014.961917
- 758 57. Howe N, Giles E, Newbury-Birch D, McColl E. Systematic review of participants' attitudes
- towards data sharing: a thematic synthesis. Journal of Health Service Research and Policy.
- 760 2018;23(2):123-33. https://doi.org/10.1177/1355819617751555
- 761 58. Street J, Fabrianesi B, Adams C, Flack F, Smith M, Carter S, et al. Sharing administrative
- health data with private industry: A report of two citizens juries. Health Expectations. 2021; May
- 763 https://doi.org/10.1111/hex.13268
- 764 59. N-Vivo Available from http://<u>gsrinternational.com/nvivo/home</u>